Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 02, 2024 | May 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 02, 2024 · Filed May 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,485.82 |
Ending reported balance
After 2024-05-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-02 · Exercise / conversion · Acquired 29,350 · Balance 33,835.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Row 2 · 2024-05-02 · Sale · Disposed 12,207 · Balance 21,628.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2024-05-02 · Sale · Disposed 17,143 · Balance 4,485.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2024-05-10 | Direct | 0 |
Reported balance
After 2024-05-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-02 · Exercise / conversion · Disposed 29,350 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Living Trust | 4,038,377 |
Reported balance
Holding disclosure · report date 2024-05-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,038,377 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2017 Filed May 4, 2017 23:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 48,900 | $25.48 | $1,245,972.00 |
DisclosureSEC source: 0001225208-17-009193 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,883.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,900 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 37,200 | $109.61 | $4,077,439.92 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $108.91 to $109.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 11,900 | $110.32 | $1,312,755.64 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,183.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $109.91 to $110.84. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 28, 2017 Filed May 2, 2017 00:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-17-008740 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,083.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 23:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 654 | $94.07 | $61,521.78 |
DisclosureSEC source: 0001225208-17-007561 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,983.82 F1 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-006521 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 49,100 | $94.03 | $4,616,941.74 |
DisclosureSEC source: 0001225208-17-006521 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $93.63 to $94.45. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-17-006521 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-003761 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,100 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 48,148 | $89.61 | $4,314,730.06 |
DisclosureSEC source: 0001225208-17-003761 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $89.22 to $90.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 952 | $90.33 | $85,990.45 |
DisclosureSEC source: 0001225208-17-003761 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,785.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $90.22 to $90.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-17-003761 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 13, 2017 Filed Jan 17, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-17-001188 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,200 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 13, 2017 Filed Jan 17, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 27,500 | $97.41 | $2,678,744.75 |
DisclosureSEC source: 0001225208-17-001188 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $97.17 to $97.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 13, 2017 Filed Jan 17, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 21,600 | $96.66 | $2,087,765.28 |
DisclosureSEC source: 0001225208-17-001188 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,137.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $96.17 to $97.16. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| January 13, 2017 Filed Jan 17, 2017 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-17-001188 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-16-043611 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,700 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · balance_after: Although the balance indicates that there are 54,700 derivative securities beneficially owned following the reported transaction, the correct number should be 245,300 due to a software issue that the vendor is working to correct. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 49,100 | $91.96 | $4,515,059.24 |
DisclosureSEC source: 0001225208-16-043611 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $91.34 to $92.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| December 19, 2016 Filed Dec 20, 2016 21:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-16-043611 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 23:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-16-042231 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F7 · balance_after: Although the balance indicates that there are 5,600 derivative securities beneficially owned following the reported transaction, the correct number should be 294,400. This is a filing software issue which the vendor is working to correct. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 23:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 25,700 | $84.78 | $2,178,869.13 |
DisclosureSEC source: 0001225208-16-042231 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $84.50 to $85.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 23:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,700 | $84.18 | $1,574,166.00 |
DisclosureSEC source: 0001225208-16-042231 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,337.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $83.50 to $84.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 23:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,700 | $86.05 | $404,424.19 |
DisclosureSEC source: 0001225208-16-042231 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,037.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $85.50 to $86.60. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 23:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-16-042231 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 27, 2016 Filed Oct 29, 2016 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-16-040816 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 27, 2016 Filed Oct 29, 2016 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 20,099 | $91.97 | $1,848,422.62 |
DisclosureSEC source: 0001225208-16-040816 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F6 · price: This transaction was executed in multiple trades at prices ranging from $91.32 to $92.31. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 27, 2016 Filed Oct 29, 2016 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 15,900 | $92.79 | $1,475,291.04 |
DisclosureSEC source: 0001225208-16-040816 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,736.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F5 · price: This transaction was executed in multiple trades at prices ranging from $92.33 to $93.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 27, 2016 Filed Oct 29, 2016 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 9,101 | $93.71 | $852,845.61 |
DisclosureSEC source: 0001225208-16-040816 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,636.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $93.33 to $94.31. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 27, 2016 Filed Oct 29, 2016 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,000 | $94.64 | $378,574.40 |
DisclosureSEC source: 0001225208-16-040816 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,737.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $94.36 to $95.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| October 27, 2016 Filed Oct 29, 2016 00:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-16-040816 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001225208-16-038850 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,600 Underlying: Common Stock · 49,100 shares Expires 2017-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 44,200 | $115.14 | $5,089,020.04 |
DisclosureSEC source: 0001225208-16-038850 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,637.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.50 to $115.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,900 | $115.66 | $566,725.67 |
DisclosureSEC source: 0001225208-16-038850 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,837.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F3 · price: This transaction was executed in multiple trades at prices ranging from $115.50 to $115.94. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 49,100 | $25.48 | $1,251,068.00 |
DisclosureSEC source: 0001225208-16-038850 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,737.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.